Skip to main content
SpringerLink
Log in

“New” Coagulation Inhibitors

  • Conference paper
New Trends in Haemostasis

  • 68 Accesses

Abstract

Blood coagulation proceeds through a series of reactions in which plasma zymogens of serine proteases are sequentially activated by limited proteolytic cleavage. Studies concerning the regulation of this process have focused on protease inhibitors that, with the exception of α2-macroglobulin, belong to the SERPIN family of protease inhibitors — for example antithrombin III, heparin cofactor II, α1-antitrypsin, Cl esterase inhibitor and plasminogen activator inhibitor 1. Recently, two “new” protease inhibitors that may regulate coagulation have been identified, and both belong to the Kunitz family of protease inhibitors. One is referred to as the lipoprotein-associated coagulation inhibitor (LACI) (Broze et al., 1987a), or extrinsic pathway inhibitor (EPI) (Rao and Rapaport, 1987). This inhibitor inactivates factor Xa directly, and in a factor Xa dependent manner also inhibits the factor VIIa/tissue factor (VIIa/TF) catalytic complex. The other inhibitor appears to represent a form of the Alzheimer β-amyloid precursor protein, is released by stimulated platelets, and inhibits factor XIa.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Antonini E, Ascenzi P, Menegatti E, Guarneri M (1983) Multiple intermediates in the reaction of bovine ß-trypsin with bovine pancreatic trypsin inhibitor ( Kunitz ). Biopolymers 22: 363–375

    Google Scholar 

  • Broze GJ, Jr, Miletich JP (1987a) Characterization of the inhibition of tissue factor in serum. Blood 69: 150–155

    PubMed  Google Scholar 

  • Broze GJ, Jr, Miletich JP (1987b) Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells. Proc Natl Acad Sci USA 84: 1886–1890

    Article  PubMed  CAS  Google Scholar 

  • Broze GJ, Jr, Warren LA, Novotny WF, Roesch KM, Miletich JP (1987) Properties of the lipoprotein-associated coagulation inhibitor produced by HepG2 cells. Blood 70: 385 (abstr)

    Google Scholar 

  • Broze GJ, Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP (1988) The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 71: 335–343

    Google Scholar 

  • Broze GJ, Jr, Higuchi DA, Smith RP (1989) The Alzheimer ß-amyloid precursor protein is a coagulation factor XIa inhibitor. Blood 74 (Suppl 1): 56a

    Google Scholar 

  • de Sauvage F, Octave JN (1989) A novel mRNA of the A4 amyloid precursor gene coding for a possibly secreted protein. Science 245: 651–653

    Article  PubMed  Google Scholar 

  • Gebhard W, Tschesche H, Fritz H (1986) Biochemistry of aprotinin and aprotinin-like inhibitors. In A.J. Barrett and G. Salvesen (Eds.), Protease Inhibitors. Amsterdam: Elsevier Science Publishers BV, 375–383

    Google Scholar 

  • Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ, Jr (1989a) Functional significance of the Kunitz-type inhibitor domains of lipoprotein-associated coagulation inhibitor. Nature 338: 518–520

    Article  PubMed  CAS  Google Scholar 

  • Girard TJ, McCourt D, Novotny WF, MacPhail LA, Likert KM, Broze GJ, Jr (1989b) The lipoprotein-associated coagulation inhibitor is phosphorylated at serine-2. Blood 74: 95a (abstr)

    Google Scholar 

  • Hjort PF (1957) Intermediate reactions in the coagulation of blood with tissue thromboplastin. Scand J Clin Lab Invest 9: (Suppl. 27): 1–182

    CAS  Google Scholar 

  • Hubbard AR, Jennings CA (1986) Inhibition of tissue thromboplastin-mediated blood coagulation. Thromb Res 42: 489–498

    Article  PubMed  CAS  Google Scholar 

  • Kang J et al (1987) The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell surface receptor. Nature 325: 733–736

    Article  PubMed  CAS  Google Scholar 

  • Laskowski M, Jr, Kato I (1980) Protein inhibitors of proteinases. Ann Rev Biochemistry 49: 593–626

    Article  CAS  Google Scholar 

  • Leytus SP, Foster DC, Kurachi K, Davie EW (1986) Gene for human factor X: A blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C. Biochemistry 25: 5098–5102

    Google Scholar 

  • Morrison JF (1982) The slow-binding and slow, tight-binding inhibition of enzyme-catalyzed reactions. Trends Biochem Sci 7: 102–105

    Article  CAS  Google Scholar 

  • Morrison SA, Jesty J (1984) Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma. Blood 63: 1338–1347

    PubMed  CAS  Google Scholar 

  • Novotny WF, Girard TJ, Miletich JP, Broze GJ, Jr (1989) Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 264: 18832–18837

    PubMed  CAS  Google Scholar 

  • Oltersdorf T et al (1989) The secreted form of the Alzheimer’s amyloid precursor protein is protease nexin-II. Nature 341: 144–147

    Article  PubMed  CAS  Google Scholar 

  • Ponte P et al (1988) A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature 331: 525–527

    Article  PubMed  CAS  Google Scholar 

  • Rao LVM, Rapaport SI (1987) Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 69: 645–651

    PubMed  CAS  Google Scholar 

  • Sanders NL, Bajaj SP, Zivelin A, Rapaport SI (1985) Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood 66: 204–212

    PubMed  CAS  Google Scholar 

  • Schneider CL (1947) The active principle of placental toxin: thromboplastin; its inactivator in blood: antithromboplastin. Am J Physiol 149: 123–129

    PubMed  CAS  Google Scholar 

  • Soons H, Hemker HC, Tans G (1986) The effect of platelets in the activation of human blood coagulation factor IX by factor XIa. Blood 68: 140–148

    PubMed  CAS  Google Scholar 

  • Thomas L (1947) Studies on the intravascular thromboplastin effect of tissue suspensions in mice:II. A factor in normal rabbit serum which inhibits the thromboplastin effect of the sedimentable tissue component. Bull Johns Hopkins Hosp. 81: 26–42

    PubMed  CAS  Google Scholar 

  • Walsh PN, Kueppers F, Seaman FS, Blankstein KB (1987) Regulation of factor XIa activity by platelets and al-protease inhibitor. J Clin Invest 80: 1578–1586

    Article  PubMed  CAS  Google Scholar 

  • Warn-Cramer BJ, Rao LV, Maki SL, Rapaport SL (1988) Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb Haemost 60: 453–456

    PubMed  CAS  Google Scholar 

  • Wenzel HR, Tschesche H (1981) Chemical mutation by amino acid exchange in the reactive site of a proteinase inhibitor and alteration of its inhibitor specificity. Angew Chem Int Ed 20: 295–296

    Article  Google Scholar 

  • Wun T-C, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ, Jr (1988) Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 263: 6001–6004

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, The Jewish Hospital at Washington University Medical Center, 216 So. Kingshighway Blvd., St. Louis, MO, 63110, USA

    G. J. Broze Jr., T. J. Girard, W. F. Novotny & R. P. Smith

Authors
  1. G. J. Broze Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. J. Girard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. F. Novotny
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. P. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. I. Medizinische Klinik, Fakultät Klinische Medizin Mannheim, Ruprecht-Karls-Universität Heidelberg, Theodor-Kutzer-Ufer, 6800, Mannheim, Germany

    Job Harenberg , Dieter L. Heene  & Gerd Stehle ,  & 

  2. Karlstraße 4, 6900, Heidelberg, Germany

    Gotthard Schettler (Leiter, Präsident der Heidelberger Akademie der Wissenschaften (bis 30.9 1990) (Leiter, Präsident der Heidelberger Akademie der Wissenschaften (bis 30.9 1990)

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Broze, G.J., Girard, T.J., Novotny, W.F., Smith, R.P. (1990). “New” Coagulation Inhibitors. In: Harenberg, J., Heene, D.L., Stehle, G., Schettler, G. (eds) New Trends in Haemostasis. Veröffentlichungen aus der Geomedizinischen Forschungsstelle der Heidelberger Akademie der Wissenschaften, vol 1990 / 1990/3. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84318-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-84318-1_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-53275-0

  • Online ISBN: 978-3-642-84318-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation